mRNA Technology Newsletter
Issue #41June 15, 20267 studies

Buffer choice affects mRNA vaccine performance by 40% after freeze-thaw cycles

This week brought major advances in mRNA delivery science, from discovering how storage conditions dramatically affect vaccine performance to engineering new ways to target specific organs and overcome treatment resistance.

🧪 Storage Buffer Chemistry Controls mRNA Vaccine Success

  • Switching from standard buffers to optimized Tris formulations improved mRNA vaccine performance by up to 40% after freeze-thaw cycles, with different buffers creating distinct internal structures in lipid nanoparticles
  • Citrate buffers enhanced fresh vaccine efficiency by promoting earlier transition to the fusogenic phase needed for cellular delivery, while Tris buffers (50-150 mM) prevented damage during freezing by forming protective mRNA-rich structures
  • The study tested three major ionizable lipids (LP-01, MC3, SM-102) used in clinical vaccines and found that buffer concentration governs both particle organization and the amount of excess lipid available for endosomal escape

Why it matters: Simple buffer optimization could significantly improve mRNA vaccine stability and effectiveness without requiring new delivery technologies—a finding that could enhance both existing COVID vaccines and future mRNA therapeutics.

🥈 Top 2% journal 🔗 ACS nano Journal Article 🗓️ Jun 12

Key Findings

🎯 Lipid Chemistry Predicts Heart-Targeting Success

  • Different lipid nanoparticle formulations showed dramatically different organ targeting after injection—some stayed at the injection site while others preferentially accumulated in liver or lungs
  • Particles that efficiently reached the liver generated stronger liver-resident T cell immunity and improved control of liver tumors in mice, demonstrating that lipid composition directly controls where immune responses develop
  • The study compared multiple clinical-grade lipid formulations and found that tuning lipid composition can direct therapeutic effects to specific tissues where protection is most needed
💡 Rational lipid design could enable precision targeting of mRNA vaccines to generate immunity exactly where diseases strike.
🥇 Top 1% journal 🔗 Nature biomedical engineering Journal Article 🗓️ Jun 12

🔬 Cellular Uptake Doesn't Guarantee mRNA Success

  • Antibody-targeted lipid nanoparticles showed that successful cellular internalization doesn't necessarily predict effective mRNA delivery—some particles entered cells but failed to release their cargo
  • Testing multiple clinically relevant T and B cell receptors revealed that post-internalization trafficking is critical for cytosolic mRNA release and protein translation
  • The findings challenge the assumption that receptor abundance predicts delivery success, showing that intracellular processing pathways matter more than uptake alone
💡 Optimizing targeted mRNA delivery requires understanding what happens after particles enter cells, not just how to get them inside.
🥉 Top 5% journal 🔗 Small science Journal Article 🗓️ Jun 11

💡 Lipid Clearance Becomes Predictable

  • Researchers developed the first computational method to predict how quickly ionizable lipids clear from the body based on simple lipophilicity calculations—a critical safety factor for repeated mRNA dosing
  • The study focused on squaramide-based ionizable lipids with ester linkers and demonstrated that chemical modifications can tune clearance rates to balance efficacy with long-term safety
  • This represents the first predictive tool for lipid behavior relevant to both therapeutic effectiveness and safety, addressing a major challenge in lipid nanoparticle development
💡 Computational prediction of lipid clearance could accelerate development of safer mRNA therapeutics for chronic diseases requiring repeated dosing.
🥉 Top 5% journal 🔗 Small science Journal Article 🗓️ Jun 11

🧬 Circular RNA Shows Sustained Expression Advantage

  • Direct comparison of linear versus circular RNA vaccines revealed that circular RNA provided prolonged protein expression compared to traditional linear mRNA vaccines
  • Both circular RNA with unmodified nucleosides and linear RNA with modified nucleosides (m1Ψ) achieved higher neutralizing antibody responses than unmodified linear RNA in influenza vaccine tests
  • Safety profiles were comparable across all platforms, with temporary decreases in blood cell counts recovering to normal by day 14 in all groups
💡 Circular RNA vaccines may offer sustained protein expression for applications requiring longer-lasting therapeutic effects.
🥉 Top 5% journal 🔗 Molecular therapy. Nucleic acids Journal Article 🗓️ Jun 12

🎯 Liver Fibrosis Reversed by mRNA-Generated Therapeutic Cells

  • Lipid nanoparticles delivering CSF1 mRNA directly generated therapeutic macrophages with anti-fibrotic properties inside the liver, avoiding the complexity and cost of ex vivo cell therapy
  • The in vivo-generated macrophages showed increased collagenase expression, enhanced phagocytic activity, and transcriptomic profiles closely resembling expensive ex vivo-induced therapeutic macrophages
  • This approach significantly reduced fibrosis in multiple mouse models, providing proof-of-concept for non-cellular alternatives to cell-based therapies
💡 mRNA-based in situ cell reprogramming could replace costly cell therapies with simpler, scalable treatments for fibrotic diseases.
🥉 Top 5% journal 🔗 Journal of nanobiotechnology Journal Article 🗓️ Jun 9

🔬 Dual Ionizable Lipids Boost Self-Amplifying RNA

  • A novel five-component lipid nanoparticle combining two clinical ionizable lipids (ALC-0315 and SM-102) achieved superior mRNA delivery and enhanced target protein expression compared to conventional four-component formulations
  • Self-amplifying RNA delivered in these particles showed gradual protein production peaking at day 7 with 4.3-fold higher copy numbers than regular mRNA, confirming active intracellular replication
  • The dual-lipid approach maintained high encapsulation efficiency (>80%) for both mRNA and self-amplifying RNA while providing controlled particle size (80-120 nm)
💡 Combining clinical-grade ionizable lipids could enhance both immediate mRNA vaccines and next-generation self-amplifying RNA platforms.
Top 30% journal 🔗 ChemMedChem Journal Article 🗓️ Jun 9

Implications

These advances reveal that mRNA therapeutic success depends heavily on engineering the delivery vehicle—from buffer chemistry that controls internal structure to lipid combinations that determine organ targeting. The emergence of predictive tools for lipid behavior and the demonstration of sustained effects with circular RNA and self-amplifying platforms suggest mRNA medicine is evolving from proof-of-concept to precision-engineered therapeutics.

Studies in this issue

Primary sources used for this newsletter.

  1. Creating special immune cells in the body using mRNA to reduce liver scarring
    key findingJournal of nanobiotechnology2026-06-09PMID 42265549
  2. Comparison of production, immune response, and safety between linear and circular RNA vaccines
    key findingMolecular therapy. Nucleic acids2026-06-12PMID 42282251